Google
ILMN 株価分析 — Illumina Inc (Healthcare >> Diagnostics & Research)
ILMN に関するよくある質問
ILMNのPER（株価収益率）は？
Illumina Inc（ILMN）は現在PER 37.61倍で取引されています。
ILMNのROE（自己資本利益率）は？
Illumina IncのROEは29.07%です。
ILMNの配当利回りは？
Illumina Incの配当利回りは0.00%です。
ILMNの品質スコア（Quality Score）は？
当社のAIはILMNの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ILMNは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ILMNはどのセクターに属しますか？
Illumina IncはHealthcare >> Diagnostics & Researchセクターに分類されます（NASDAQ市場）
ILMN AI Analysis Summary
Our AI summary for ILMN: Illumina Inc (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 37.61, ROE of 29.07%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 205.10
Price
0.01
(0.00%)
Day Change
|
|
|---|
ILMN, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
1294
|
| Magic Formula Rank by ROE |
1294
|
| Magic Formula Rank by ROIC |
1334
|
| Price | 205.10 |
| PBV / Sector |
10.93 / -29.69
|
| Earning Per Share | 5.45 |
| PE / Sector |
37.61 / 48.18
|
| PEG or PE/Growth / Sector |
-0.47 / 1.64
|
| Average 1M Daily Value |
353.45 M
GREAT
|
| Average 1W Daily Value |
492.55 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
54% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:00 |
| Symbol | ILMN |
| Name | ILLUMINA INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 151.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 31,030.12 / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5200 Illumina Way, San Diego, CA, United States, 92122
Phone: 858 202 4500
Website: https://www.illumina.com
Employees: 8,600
Description: Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
